Hansen L B, Larsen N E
Psychopharmacology (Berl). 1977 Jul 18;53(2):127-30. doi: 10.1007/BF00426481.
Plasma concentrations of perphenazine (PPZ) (Trilafon) and perphenazinesulphoxide (PPZSO) were estimated during a 2-week period in 16 patients receiving peroral PPZ treatment for various psychotic disorders. The results demonstrated that the average concentration of three plasma samples was a reasonably good expression of the steady-state plasma level despite a great fluctuation in the concentration from sample to sample. Increased doses in three of the patients resulted in disproportionate increases in the plasma levels. Neurological side effects were recorded and their relation to plasma concentrations are discussed.
在为期2周的时间里，对16例因各种精神障碍接受口服奋乃静（PPZ，商品名：Trilafon）治疗的患者，测定了其血浆中奋乃静（PPZ）和奋乃静亚砜（PPZSO）的浓度。结果表明，尽管各样本间浓度波动很大，但三份血浆样本的平均浓度仍能较好地反映稳态血浆水平。三名患者增加剂量后，血浆水平出现不成比例的升高。记录了神经副作用，并讨论了其与血浆浓度的关系。
